UK-based binx health has collaborated with McKesson, a global healthcare company, for the sale and distribution of the binx io platform in the US, it was reported on Tuesday.
The binx io is an FDA approved infectious disease platform that provides results in about thirty minutes and allows diagnosis and treatment of chlamydia and gonorrhoea to take place in a single visit. It has demonstrated to be on par with central-laboratory testing. It is also likely to be used in satellite point-of-care settings designated under such moderate or high complexity certificates.
Jeffrey Luber, binx health's chief executive officer, stated: "At binx we consider evidence-based care and consumer convenience central to all we do. Today's announcement is a win-win-win for clinics, patients and the public health and we are especially proud of this new distribution partnership for national reach."
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial